MedAdvisor Ltd (ASX: MDR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
MedAdvisor Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$118.66 million
P/E Ratio
165.38
Dividend Yield
0.00%
Shares Outstanding
551.89 million
Earnings per share
0.001
Dividend per share
N/A
Year To Date Return
N/A
Earnings Yield
0.60%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
MedAdvisor Ltd (ASX: MDR)
Latest News
Share Market News
MedAdvisor Ltd (ASX:MDR) share price halted ahead of transformational $49 million acquisition
Speculative
3 small cap ASX healthcare shares to watch closely in the 2020s
Share Market News
Add these 3 ASX medical technology companies to your watch list
Speculative
3 exciting small cap ASX healthcare shares to watch
Speculative
3 exciting small cap ASX shares to watch very closely
Speculative
3 exciting small cap ASX healthcare shares to watch
Speculative
3 exciting ASX healthcare shares to watch in the 2020s
⏸️ ASX Shares
3 small cap ASX healthcare shares with enormous potential
Coronavirus News
Coronavirus: This ASX tech share is rocketing higher after telehealth launch
Coronavirus News
Why this ASX medical tech share is up 22% today
Share Market News
Why this ASX medical technology share surged 43% higher today
Share Gainers
MedAdvisor share price rockets 15% higher on UK update
MDR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About MedAdvisor Ltd
MedAdvisor Ltd is engaged in the development and deployment of the MedAdvisor medication and adherence platform. The MedAdvisor platform is focused on improving health outcomes by connecting health professionals with their patients using mobile and web technologies. It has three reporting segments: ANZ Operations, U.S. Operations and UK Operations. The company derives majority of its revenues from U.S. Operations.
MDR Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Dec 2024 | $0.22 | $-0.06 | -22.22% | 3,158,935 | $0.22 | $0.23 | $0.21 |
| 19 Dec 2024 | $0.27 | $-0.02 | -7.02% | 287,483 | $0.28 | $0.28 | $0.25 |
| 18 Dec 2024 | $0.29 | $-0.01 | -3.45% | 68,938 | $0.29 | $0.29 | $0.28 |
| 17 Dec 2024 | $0.29 | $0.01 | 3.57% | 2,843,825 | $0.27 | $0.29 | $0.27 |
| 16 Dec 2024 | $0.28 | $-0.02 | -6.67% | 275,786 | $0.30 | $0.30 | $0.28 |
| 13 Dec 2024 | $0.30 | $0.00 | 0.00% | 28,319 | $0.30 | $0.30 | $0.30 |
| 12 Dec 2024 | $0.30 | $0.00 | 0.00% | 1,798,613 | $0.30 | $0.31 | $0.30 |
| 11 Dec 2024 | $0.30 | $-0.02 | -6.35% | 162,216 | $0.30 | $0.30 | $0.30 |
| 10 Dec 2024 | $0.32 | $0.00 | 0.00% | 21,176 | $0.30 | $0.32 | $0.30 |
| 09 Dec 2024 | $0.32 | $0.00 | 0.00% | 182,060 | $0.31 | $0.32 | $0.30 |
| 06 Dec 2024 | $0.32 | $-0.01 | -3.08% | 37,439 | $0.31 | $0.32 | $0.31 |
| 05 Dec 2024 | $0.33 | $0.02 | 6.56% | 104,464 | $0.31 | $0.33 | $0.31 |
| 04 Dec 2024 | $0.31 | $0.01 | 3.33% | 4,097 | $0.30 | $0.31 | $0.30 |
| 03 Dec 2024 | $0.30 | $0.01 | 3.45% | 303,603 | $0.30 | $0.31 | $0.29 |
| 02 Dec 2024 | $0.29 | $-0.02 | -6.45% | 179,153 | $0.31 | $0.31 | $0.29 |
| 29 Nov 2024 | $0.31 | $0.00 | 0.00% | 40,880 | $0.31 | $0.31 | $0.30 |
| 28 Nov 2024 | $0.31 | $0.03 | 10.53% | 511,952 | $0.29 | $0.31 | $0.29 |
| 27 Nov 2024 | $0.29 | $-0.01 | -3.45% | 393,639 | $0.29 | $0.29 | $0.28 |
| 26 Nov 2024 | $0.29 | $0.01 | 3.57% | 57,049 | $0.30 | $0.30 | $0.29 |
| 25 Nov 2024 | $0.28 | $-0.01 | -3.45% | 331,357 | $0.30 | $0.30 | $0.28 |
| 22 Nov 2024 | $0.29 | $-0.01 | -3.33% | 748,484 | $0.30 | $0.31 | $0.29 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 14 Nov 2024 | Richard (Rick) Ratliff | Issued | 760,059 | $220,417 |
Issue of options.
|
| 30 Oct 2024 | Lucas Merrow | Expiry | 750,000 | $262,500 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Catherine (Kate) Jane Hill | Non-Executive Director | May 2023 |
Ms Hill is auditor and business advisor with over 30 years of experience of working with privately owned and ASX-listed companies across a range of business issues. A former senior partner and first female board member of top 4 accounting firm Deloitte, she has in recent years turned her focus, her energies, and experience into Non-Executive Director roles. She is a director of small to mid-cap companies listed on ASX and other global exchanges, with a track record in change involving new business models, new markets, and new technologies. She is chair of Risk Committee and member of People Committee.
|
| Mr Jim Xenos | Non-Executive Director | Nov 2015 |
Mr Xenos is currently the Chief Executive Officer of NostraData Pty Limited, which he co-founded in 2010. Prior to co-founding NostraData, Jim held several Associate Director positions with GlaxoSmithKline PLC. Jim was also the Head of Retail at Sigma Healthcare Limited for Herron Pharmaceuticals. She is Chair of people committee.
|
| Ms Linda Jenkinson | Non-Executive ChairmanNon-Executive Director | Feb 2022 |
Ms Hill is auditor and business advisor with over 30 years' experience of working with privately owned and ASX-listed companies across a range of business issues. A former senior partner and first female board member of top 4 accounting firm Deloitte, she has in recent years turned her focus, her energies, and experience into Non-Executive Director roles. She is aa director of small to mid-cap companies listed on ASX and other global exchanges, with a track record in change involving new business models, new markets, and new technologies. She is chair of Risk Committee and member of People Committee.
|
| Mr Lucas Merrow | Non-Executive Director | Aug 2021 |
Mr Merrow co-founded and served as the Chief Executive Officer of Eliza Corporation-the leader in health engagement management and patient communications. Eliza Corporation was later acquired. Prior to the founding of Eliza Corporation, Lucas co-founded and served as the Chief Operating Officer of Adheris Health, a leading firm in prescription adherence and patient education programs in the United States. MedAdvisor acquired Adheris Health in November 2020. He is Member of People Committee.
|
| Mr Richard (Rick) Ratliff | Chief Executive OfficerManaging Director | Jul 2022 |
Mr Ratliff spent over 30 years in the healthcare and pharmaceutical technology sector in key markets in which MedAdvisor Solutions operates. He has led the development of several large-scale technology-enabled healthcare businesses within global organizations such as IBM and Accenture as well as via start-up and early-stage businesses, including Healthvision, Surescripts, and ConnectiveRx. Rick also worked with the Australian federal government to develop and deliver My Health Record, the leading online EHR available to all Australian citizens. He is a member of People Committee.
|
| Mr Kevin Hutchinson | Non-Executive Director | Nov 2022 |
Mr Hutchinson is an entrepreneur with 30 years of experience in the tech industry. He has built and grown companies that deliver innovative services by using disruptive technology. He also has seen great success in his ability to accelerate growth by hiring and developing teams that drive exceptional results. He has served in numerous C-level executive roles, including CEO and COO, as well as several non-executive board appointments. Kevin is CEO and Director of AXL Health and on the Board of Matrix Analytics dba eon Health. He is a member of Risk Committee.
|
| Ms Gillian Maria Nairn | Joint Company Secretary | Dec 2024 |
-
|
| Ms Ancila Desai | Chief Financial OfficerCompany Secretary | Feb 2023 |
-
|
| Ancila Desai | Chief Financial OfficerCompany Secretary |
-
|
|
| Gillian Maria Nairn | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Guild Group Holdings Limited | 94,905,130 | 17.21% |
| HSBC Custody Nominees (Australia) Limited | 84,152,463 | 15.26% |
| Ebos Ph Pty Ltd | 53,986,823 | 9.79% |
| J P Morgan Nominees Australia Pty Limited | 45,226,380 | 8.20% |
| Cotiviti Inc | 43,999,999 | 7.98% |
| Citicorp Nominees Pty Limited | 38,361,455 | 6.96% |
| National Nominees Limited | 14,892,708 | 2.70% |
| UBS Nominees Pty Ltd | 14,289,149 | 2.59% |
| Bond Street Custodians Limited <Salter - D79836 A/C> | 9,700,000 | 1.76% |
| Kojent Pty Ltd <Kojent A/C> | 6,846,956 | 1.24% |
| Indcorp Consulting Group Pty Limited <Superannuation Fund A/C> | 6,550,000 | 1.19% |
| Romida Enterprises Pty Ltd <Romida Family A/C> | 5,642,935 | 1.02% |
| Gread Management Pty Limited <The A G & R R Family A/C> | 5,344,283 | 0.97% |
| Provare Pty Ltd <Provare Investment A/C> | 3,743,419 | 0.68% |
| Tagdime Pty Ltd <Ian M Davison P/L S/F A/C> | 3,264,316 | 0.59% |
| Dr Christopher Harold Benton | 3,000,000 | 0.54% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 2,815,940 | 0.51% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 2,383,158 | 0.43% |
| Dmx Capital Partners Limited | 2,351,551 | 0.43% |
| Wavey Industries Pty Ltd <Josh Swinnerton Family A/C> | 2,300,000 | 0.44% |
